Preferred Label : Anti-LIV-1 Antibody-drug Conjugate BRY812;
NCIt synonyms : Anti-LIV-1/MMAE ADC BRY812; Anti-LIV-1 ADC BRY812;
NCIt definition : An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed
against solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6)
that is conjugated, via a linker, to the cytotoxic agent monomethyl auristatin E (MMAE),
with potential antineoplastic activity. Upon administration and binding to LIV-1-positive
tumor cells, BRY812 enters the tumor cell lysosome through endocytosis, and releases
MMAE. MMAE binds to and inhibits tubulin polymerization, which may result in G2/M
phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a multi-pass
transmembrane protein and zinc transporter, is expressed in several types of solid
tumors and plays a key role in tumor cell progression, proliferation and metastasis.
The conjugation method and linkage system prevent MMAE from separating from the antibody
during circulation, thereby limiting off target toxicity.;
Molecule name : BRY-812; BRY 812;
Origin ID : C201827;
concept_is_in_subset
- has_target
